Urinary retention following repeated high-dose quetiapine [3]

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 899-900

  Sokolski, Kenneth N ^a   Brown, Brenda J ^a   Melden, Mark ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; LORAZEPAM; QUETIAPINE;

ADULT; AGITATION; CASE REPORT; CATHETERIZATION; DRUG MEGADOSE; EMERGENCY WARD; FEMALE; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SIDE EFFECT; ULTRASOUND; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 1942534670     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D502     Document Type: Letter

References (5)

1. Goldstein JM, Brecher M. Clarification of anticholinergic effects of quetiapine (letter). J Clin Psychiatry 2000;61:9.
2. Watts D, Wax P. Physostigmine administration for quetiapine toxicity (abstract 1-265). Presented at: North American Congress of Clinical Toxicology Annual Meeting, Chicago, September 4-9, 2003:641.
3. Garver DL. Review of quetiapine side effects. J Clin Psychiatry 2000; 61(suppl 8):31-3.
4. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.